Steven M. Albelda, MD

faculty photo
William Maul Measey Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
1016B Abramson Research Center
3615 Civic Center Boulevard
Philadelphia, PA 19104
Office: (215) 573-9933
Fax: (215) 573-4469
B.A. (Chemistry)
Williams College, 1975.
University of Pennsylvania, 1979.
Permanent link

Description of Research Expertise

Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).

Selected Publications

David Holt, Olugbenga Okusanya, Ryan Judy, Ollin Venegas, Jack Jiang, Elizabeth De Jesus, Evgeniy Eruslanov, Jon Quatromoni, Pratik Bhojnagarwala, Charuhas Deshpande, Steven Albelda, Shuming Nie, Sunil Singhal: Intraoperative Near-Infrared Imaging Can Distinguish Cancer from Normal Tissue but Not Inflammation. PLOS One 9(7): e103342, July 2014.

Moon EK1, Wang LC2, Dolfi DV3, Wilson CB4, Ranganathan R2, Sun J2, Kapoor V2, Scholler J4, Puré E5, Milone MC4, June CH4, Riley JL3, Wherry EJ3, Albelda SM2.: Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. Clinical Cancer Research 20(16): 1-12, June 2014.

Quatromoni JG, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E.: An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. Journal of Leukocyte Biology 2014.

Schwed Lustgarten Daniel E, Thompson Jeffrey, Yu Gordon, Vachani Anil, Vaidya Bhavesh, Rao Chandra, Connelly Mark, Udine Michelle, Tan Kay See, Heitjan Daniel F, Albelda Steven: Use of Circulating Tumor Cell Technology (CELLSEARCH®) for the Diagnosis of Malignant Pleural Effusions. Annals of the American Thoracic Society Nov 2013.

Baek Kwan-Hyuck, Bhang Dongha, Zaslavsky Alexander, Wang Liang-Chuan, Vachani Anil, Kim Carla F, Albelda Steven M, Evan Gerard I, Ryeom Sandra: Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. The Journal of clinical investigation 123(10): 4375-89, Oct 2013.

Liu Yujie, Wang Liqing, Predina Jarrod, Han Rongxiang, Beier Ulf H, Wang Liang-Chuan S, Kapoor Veena, Bhatti Tricia R, Akimova Tatiana, Singhal Sunil, Brindle Paul K, Cole Philip A, Albelda Steven M, Hancock Wayne W: Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity. Nature medicine 19(9): 1173-7, Sep 2013.

Stevenson James P, Kindler Hedy L, Papasavvas Emmanouil, Sun Jing, Jacobs-Small Mona, Hull Jennifer, Schwed Daniel, Ranganathan Anjana, Newick Kheng, Heitjan Daniel F, Langer Corey J, McPherson John M, Montaner Luis J, Albelda Steven M: Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2(8): e26218, Aug 2013.

Quatromoni Jon G, Suzuki Eiji, Okusanya Olugbenga, Judy Brendan F, Bhojnagarwala Pratik, Venegas Ollin, Eruslanov Evgeniy, Predina Jarrod D, Albelda Steven M, Singhal Sunil: The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells. BMC immunology 14: 30, July 2013.

Marcela V. Maus, Andrew R. Haas, Gregory L. Beatty, Steven M. Albelda, Bruce L. Levine, Xiaojun Liu, Yangbing Zhao, Michael Kalos, and Carl H. June: T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans. Cancer Immunology Research 1(1): 26-31, July 2013.

Riese Matthew J, Wang Liang-Chuan S, Moon Edmund K, Joshi Rohan P, Ranganathan Anjana, June Carl H, Koretzky Gary A, Albelda Steven M: Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer research 73(12): 3566-77, Jun 2013.

back to top
Last updated: 06/05/2015
The Trustees of the University of Pennsylvania